Polaryx Therapeutics
Update in progressPLYX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Polaryx Therapeutics, Inc. is a clinical‑stage biotechnology company developing disease‑modifying therapies for rare pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX‑100, a preclinical oral combination therapy; PLX‑200, a repurposed oral small molecule; PLX‑300, a preclinical oral combination therapy; and PLX‑400, a preclinical gene therapy candidate. Founded in 2014, it is based in Paramus, New Jersey.
Company score
- Sentiment
- 0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Alex Yang J.D., L.L.M.
- Founded2014
- Employees2
- Websitepolaryx.com
Identifiers
- ISINUS73110F1003
- FIGIBBG01ZPFWW22